Suppr超能文献

褪黑素受体激动剂雷美尔酮通过激活线粒体钾通道减少缺血再灌注损伤。

Melatonin Receptor Agonist Ramelteon Reduces Ischemia-Reperfusion Injury Through Activation of Mitochondrial Potassium Channels.

机构信息

Department of Anesthesiology, University Hospital Düsseldorf, Düsseldorf, Germany.

Institute of Cardiovascular Physiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

出版信息

J Cardiovasc Pharmacol. 2018 Aug;72(2):106-111. doi: 10.1097/FJC.0000000000000600.

Abstract

Activation of melatonin receptors induces cardioprotection. Mitochondrial potassium channels (mKCa and mKATP) are involved in the signaling cascade of preconditioning. The melatonin receptor agonist ramelteon is an approved oral medication for treatment of insomnia, but nothing is known about possible cardioprotective properties. We investigated whether (1) ramelteon induces cardioprotection mediated by the melatonin receptor; (2) this effect is concentration-dependent; and (3) mKCa and/or mKATP channels are critically involved in ramelteon-induced cardioprotection. Hearts of male Wistar rats were randomized and placed on a Langendorff system, perfused with Krebs-Henseleit buffer at a constant pressure of 80 mm Hg. All hearts were subjected to 33 minutes of global ischemia and 60 minutes of reperfusion. Before, ischemic hearts were perfused with different concentrations of ramelteon (0.01-5 μM) for determination of a concentration-effect curve. In subsequent experiments, the lowest protective concentration of ramelteon was administered together with paxilline (mKCa channel inhibitor) and 5-hydroxydecanoate (mKATP channel inhibitor). To determine whether the reduction of ischemia and reperfusion injury by ramelteon is mediated by melatonin receptor, we combined ramelteon with luzindole, a melatonin receptor antagonist. Infarct size was determined by triphenyltetrazolium chloride staining. In control animals, infarct size was 58% ± 6%. Ramelteon in a concentration of 0.03 µM reduced infarct size to 28% ± 4% (P < 0.0001 vs. Con). A lower concentration of ramelteon did not initiate cardioprotection, and higher concentrations did not further decrease infarct size. Paxilline, 5-hydroxydecanoate, and luzindole completely blocked the ramelteon-induced cardioprotection. This study shows for the first time that (1) ramelteon induces cardioprotection through melatonin receptor; (2) the effect is not concentration-dependent; and (3) activation of mKCa and mKATP channels is involved.

摘要

褪黑素受体的激活可诱导心脏保护作用。线粒体钾通道(mKCa 和 mKATP)参与预处理的信号级联反应。褪黑素受体激动剂雷美尔酮是一种已批准用于治疗失眠的口服药物,但对于其可能的心脏保护特性尚不清楚。我们研究了(1)雷美尔酮是否通过褪黑素受体诱导心脏保护作用;(2)这种作用是否具有浓度依赖性;以及(3)mKCa 和/或 mKATP 通道是否在雷美尔酮诱导的心脏保护作用中起关键作用。雄性 Wistar 大鼠的心脏被随机分配并放置在 Langendorff 系统中,以 80mmHg 的恒定压力用 Krebs-Henseleit 缓冲液灌注。所有心脏均经历 33 分钟的整体缺血和 60 分钟的再灌注。在缺血前,用不同浓度的雷美尔酮(0.01-5μM)对心脏进行灌注,以确定浓度-效应曲线。在随后的实验中,给予最低的保护浓度的雷美尔酮,同时给予帕西林(mKCa 通道抑制剂)和 5-羟基癸酸(mKATP 通道抑制剂)。为了确定雷美尔酮通过褪黑素受体减少缺血再灌注损伤的作用,我们将雷美尔酮与褪黑素受体拮抗剂卢西酮结合使用。通过三苯基四氮唑染色测定梗死面积。在对照动物中,梗死面积为 58%±6%。浓度为 0.03μM 的雷美尔酮将梗死面积减少至 28%±4%(P<0.0001 与 Con 相比)。浓度较低的雷美尔酮不会引发心脏保护作用,而较高浓度的雷美尔酮不会进一步减少梗死面积。帕西林、5-羟基癸酸和卢西酮完全阻断了雷美尔酮诱导的心脏保护作用。这项研究首次表明,(1)雷美尔酮通过褪黑素受体诱导心脏保护作用;(2)该作用不是浓度依赖性的;以及(3)激活 mKCa 和 mKATP 通道参与其中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验